Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition that primarily affects the optic nerves and spinal cord. According to Edgar Carnero Contentti et al., 2025, the prevalence of NMOSD ranges from approximately 0.5-4 cases per 100,000 individuals worldwide. The disorder accounts for a significant burden in neuroimmunology, with growing focus on targeted immunotherapies. The NMOSD drug pipeline is expanding with advanced monoclonal antibodies and biologics aiming to reduce relapse rates and improve patient outcomes. According to the neuromyelitis optica spectrum disorder (NMOSD) pipeline analysis by Expert Market Research, the demand for NMOSD therapeutics are expected to grow steadily in the coming years.
Major companies involved in the neuromyelitis optica spectrum disorder (NMOSD) pipeline analysis include Beijing Mabworks Biotech Co., Ltd., along with Shanghai Jiaolian Drug Research and Development Co., among others.
Leading drugs currently in the pipeline include MIL62, BAT4406F, and others.
Robust NMOSD pipeline growth is driven by rising clinical trials for monoclonal antibodies, increasing R&D investments, and strategic collaborations to develop targeted immunotherapies and complement system inhibitors.
The Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into neuromyelitis optica spectrum disorder (NMOSD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for neuromyelitis optica spectrum disorder (NMOSD). The neuromyelitis optica spectrum disorder (NMOSD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The neuromyelitis optica spectrum disorder (NMOSD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with neuromyelitis optica spectrum disorder (NMOSD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to neuromyelitis optica spectrum disorder (NMOSD).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune condition that causes inflammation in the central nervous system, primarily affecting the optic nerves and spinal cord. It is often triggered by antibodies targeting aquaporin-4 (AQP4), leading to severe, recurrent relapses that may result in vision loss or paralysis.
Neuromyelitis optica spectrum disorder (NMOSD) treatments focus on relapse prevention and immune suppression. Therapies include corticosteroids, plasma exchange, and monoclonal antibodies such as eculizumab or inebilizumab, aiming to reduce disease activity and prevent long-term neurological damage. In March 2024, Ultomiris (ravulizumab-cwvz) was approved in the United States for anti-AQP4 antibody-positive NMOSD. The long-acting C5 complement inhibitor demonstrated a 98.6% relapse risk reduction in the CHAMPION-NMOSD Phase III trial.
According to Edgar Carnero Contentti et al., 2025, the global prevalence of neuromyelitis optica spectrum disorder (NMOSD) ranges from 0.5 to 4 per 100,000 individuals, with up to 10 per 100,000 in Asian and Afro-descendant populations. As per Farren B. S. Briggs et al., 2024, NMOSD prevalence in the United States is highest among black individuals (12.99/100,000). According to Caleb L. Shumway et al., 2024, NMOSD occurs predominantly in females (80%). These rising prevalence trends highlight a growing need for targeted therapies and robust drug pipeline expansion.
This section of the report covers the analysis of neuromyelitis optica spectrum disorder (NMOSD) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The neuromyelitis optica spectrum disorder (NMOSD) pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total neuromyelitis optica spectrum disorder (NMOSD) clinical trials. It accounts for 35% of the pipeline, highlighting strong mid-stage development. Phase I and III each represent 22.5%, indicating balanced early and late-stage innovations. This robust pipeline fosters continued therapeutic advancement and future market expansion in NMOSD treatment.
The drug molecule categories covered under the neuromyelitis optica spectrum disorder (NMOSD) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The neuromyelitis optica spectrum disorder (NMOSD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for neuromyelitis optica spectrum disorder (NMOSD). C5 complement inhibition therapies are rapidly advancing in the neuromyelitis optica spectrum disorder (NMOSD) drug pipeline. For instance, eculizumab, the first FDA-approved C5 inhibitor, has demonstrated significant relapse reduction in AQP-4 antibody-positive patients. Additionally, ravulizumab-cwvz, a long-acting C5 inhibitor, is under evaluation and has shown no relapses in phase 3 trials, offering a promising treatment option with extended dosing intervals for improved patient convenience.
The EMR report for the neuromyelitis optica spectrum disorder (NMOSD) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed neuromyelitis optica spectrum disorder (NMOSD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in neuromyelitis optica spectrum disorder (NMOSD) clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for neuromyelitis optica spectrum disorder (NMOSD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of neuromyelitis optica spectrum disorder (NMOSD) drug candidates.
MIL62, sponsored by Beijing Mabworks Biotech Co., Ltd., is currently undergoing a Phase Ib/III clinical trial to evaluate its safety and efficacy in patients with neuromyelitis optica spectrum disorder (NMOSD). This study aims to assess how well MIL62, a third-generation anti-CD20 antibody, performs in reducing NMOSD relapses. Developed using an ADCC-enhanced antibody platform, MIL62 targets B cells and holds multiple patents globally. The drug is showing promise across autoimmune and oncology indications and is being positioned as a potential treatment alternative for serious, life-threatening disorders.
BAT4406F is an ADCC-enhanced, fully humanized anti-CD20 monoclonal antibody currently being evaluated by Bio-Thera Solutions in a Phase II/III trial for patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for aquaporin-4 antibodies. The study is aiming to assess the drug’s efficacy and safety through a randomized, double-blind, placebo-controlled design. BAT4406F is being administered intravenously at 500 mg on Day 1 and Day 182.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for neuromyelitis optica spectrum disorder (NMOSD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into neuromyelitis optica spectrum disorder (NMOSD) collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share